Home > Insider Trading > Filing (0001628280-22-005118)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1600620	Aurinia Pharmaceuticals Inc.	AUPH	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1837648	Bindert Robert Huizinga	#1203-4464 Markham Street Victoria A1 V8Z7X8	Evp Of Research	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-03-02	8,500	$0.00	74,228	No	4	A	Direct
Common Stock	Disposition	2022-03-02	4,849	$12.01	69,379	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Restricted Stock Unit	Acquisiton	2022-03-02	62,448	$0.00	62,448	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2022-03-02	106,838	$0.00	106,838	$12.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
62,448			No	4	A	Direct
106,838		2032-03-02	No	4	A	Direct

Footnotes

On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.